$NXGL Cashflow Statement | Understand Stock

$NXGL

$4.26 +$0.29 (7.45%) Close

$NXGL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Loss attributable to non-controlling interest in joint venture
Depreciation and amortization
Share-based compensation
Gain on investment in marketable securities
Realized gain on investment in marketable securities
Change in fair value of warrant liability
Change in ROU asset and operating lease liability
Change in fair value of contingent consideration
Amortization of right of use asset
Warrant modification expense
Forgiveness of debt
Loss of extinguishment of debt
Amortization of deferred financing costs
Beneficial conversion feature in excess of face value

Gain in spin-off of NexGelRx
Changes in operating assets and liabilities:
Accounts receivable, net
Inventory
Prepaid expenses and other current assets
Accounts payable
Accounts payable – related party
Accrued expenses and other current liabilities
Partnership advance
Deferred revenue
Operating lease liability
Net Cash Used in Operating Activities
Investing Activities
Purchases of equipment
Investment in subsidiary
Proceeds from sales of marketable securities
Investments in or purchases of marketable securities
Net Cash Provided by (Used in) Investing Activities

Financing Activities
Principal payments on operating lease liability
Proceeds from notes payable
Proceeds from convertible notes
Payment of financing costs
Payment of contingent consideration
Proceeds from rights offering
Principal payments of notes payable
Principal payments on convertible notes
Proceeds from notes payable (PPP)
Proceeds from non-controlling interest
Principal payment of financing lease liability
Proceeds from margin line of credit
Net Cash Provided by Financing Activities

Net Increase (Decrease) in Cash (*)
Cash - End of period
Fair value of beneficial conversion and warrant features of Convertible Notes Payable
Original issue discounts recognized on Convertible Notes Payable
Warrants issued for debt and equity financing costs
Operating lease, ROU assets and liabilities
Common Shares issued for acquisition
Inventory acquired from acquisition
Accounts payable assumed from acquisition
Cash and restricted cash – Beginning of year
Cash and restricted cash – End of year
Supplemental Non-cash Investing and Financing Activities
Fair value of beneficial conversion and warrant features of convertible notes payable
Original issue discounts recognized on convertible notes payable
Warrants issued for debt and equity financing costs
Operating lease, ROU assets and liabilities
Property and equipment and intangibles contributed as capital investment to JV
Warrants issued in conjunction with investment in NexgelRx
Additional ROU assets and operating lease liabilities from lease modification
Shares issued in conjunction with asset acquisition
Property and equipment financed under notes payable
Property and equipment financed under financing leases
Property and equipment contributed as capital investment to JV
ROU asset and operating lease liabilities recognized upon consolidation of JV

Comments